Skip to content

Sichuan Baili Pharmaceutical Co., Ltd.

Beijing, Beijing Municipality

OncologyPhase II

What changed

Phase II trial registered: SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

9mo agoTrial registeredSep 26, 2025Source filing (opens the source filing in a new tab)

Momentum

42no change

Momentum 42 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources